RxDoctor Payments Data

Edson Deguzman, MD

Cardiovascular Disease · Midlothian, VANPI 1174512198

Payments from drug & device makers

$885in general payments, 2019–2025

Across 44 payments — averaging $20.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$226
  • Baxter Healthcare$114
  • Johnson & Johnson$87
  • Boehringer Ingelheim$83
  • Amgen$78
  • Boston Scientific$60
  • plus $239 from 8 others

What the payments were for

  • Food & beverage$885100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$885 in reported general payments places this provider in the 35th percentile of 548 cardiovascular disease providers in Virginia.

See all cardiovascular disease providers in Virginia

Medicare billing

Part B allowed, 2024
$538,377
Medicare patients
1,350
Services billed
6,348

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban446$545,541
EntrestoSacubitril/Valsartan280$385,416
EliquisApixaban305$355,582
JardianceEmpagliflozin164$195,737
Repatha SyringeEvolocumab28$29,776
Repatha SureclickEvolocumab16$21,208
FarxigaDapagliflozin Propanediol20$17,862
Metoprolol Succinate1,136$12,912
Praluent PenAlirocumab17$12,101
Flecainide Acetate123$8,525
Atorvastatin Calcium839$6,999
Losartan Potassium720$5,062
Rosuvastatin Calcium406$4,355
Amlodipine Besylate772$3,571
Ezetimibe165$3,536

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$87$545,541446 claims
NovartisEntresto$226$385,416280 claims
Boehringer IngelheimJardiance$83$195,737164 claims
AstraZenecaFarxiga$16$17,86220 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 548 cardiovascular disease providers in Virginia.

Other cardiovascular disease in Midlothian

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →